

CITATION REPORT

List of articles citing

Tadalafil therapy for sarcoidosis-associated pulmonary hype

DOI: 10.1086/688775

Pulmonary Circulation, 2016, 6, 557-562.

Source: <https://exaly.com/paper-pdf/63568832/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
27	Sarcoidosis-Associated Pulmonary Hypertension. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2017 , 38, 450-462	3.9	21
26	Sarcoidosis: Drugs under Investigation. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2017 , 38, 532-537	3.9	4
25	Sarcoidosis-associated Pulmonary Hypertension: Pathophysiology, Diagnosis, and Treatment. <i>Clinical Pulmonary Medicine</i> , 2018 , 25, 52-60	0.3	22
24	A case of sarcoidosis-associated pulmonary hypertension masquerading as chronic thromboembolic pulmonary hypertension. <i>Pulmonary Circulation</i> , 2018 , 8, 2045894018768289	2.7	4
23	Pulmonary Hypertension Associated With Sarcoidosis. 2019 , 285-303		
22	Clinical Features and Outcomes of Patients with Sarcoidosis-associated Pulmonary Hypertension. <i>Scientific Reports</i> , 2019 , 9, 4061	4.9	21
21	Advanced sarcoidosis. <i>Current Opinion in Pulmonary Medicine</i> , 2019 , 25, 497-504	3	19
20	An update on sarcoidosis-associated pulmonary hypertension. <i>Current Opinion in Pulmonary Medicine</i> , 2020 , 26, 582-590	3	6
19	Advanced Pulmonary Sarcoidosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020 , 41, 700-715	3.9	5
18	Sarcoidosis-Associated Pulmonary Hypertension. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020 , 41, 659-672	3.9	3
17	Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 201, e26-e51	10.2	202
16	Characteristics and Outcomes of Pulmonary Angioplasty With or Without Stenting for Sarcoidosis-Associated Pulmonary Hypertension: Systematic Review and Individual Participant Data Meta-Analysis. <i>Current Problems in Cardiology</i> , 2021 , 46, 100616	17.1	3
15	Sarcoidosis-Associated Pulmonary Hypertension: An Updated Review and Discussion of the Clinical Conundrum. <i>Current Problems in Cardiology</i> , 2021 , 46, 100506	17.1	4
14	Critical Care of Patients With Cardiopulmonary Complications of Sarcoidosis. <i>Journal of Intensive Care Medicine</i> , 2021 , 885066621993041	3.3	
13	Epidemiology, Pathogenesis, and Clinical Approach in Group 5 Pulmonary Hypertension. <i>Frontiers in Medicine</i> , 2020 , 7, 616720	4.9	3
12	Sarcoidosis associated pulmonary hypertension: an update. <i>Current Opinion in Pulmonary Medicine</i> , 2021 , 27, 285-295	3	1
11	A Comprehensive Review of Sarcoidosis Treatment for Pulmonologists. <i>Pulmonary Therapy</i> , 2021 , 7, 325-344	3.44	1

10	Author Response: Pulmonary Vasodilators in Sarcoidosis-associated Pulmonary Hypertension. <i>Clinical Medicine and Research</i> , 2020 , 18, 55-57	1.4	
9	Sarcoidosis-Associated Pulmonary Hypertension. <i>Respiratory Medicine</i> , 2020 , 135-146	0.2	
8	Predictive value of pulmonary function testing in the evaluation of pulmonary hypertension in sarcoidosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2018 , 35, 308-316	1.1	1
7	Long-term outcomes of epoprostenol therapy in sarcoid associated pulmonary hypertension. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2020 , 37, 184-191	1.1	0
6	Treatment of newly diagnosed sarcoid-associated pulmonary hypertension with ambrisentan and tadalafil combination therapy. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2020 , 37, 234-238	1.1	
5	WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension.. <i>European Respiratory Review</i> , 2022 , 31,	9.8	3
4	Sarcoidosis-associated pulmonary hypertension. 2022 , 234-255		
3	Comorbidities of sarcoidosis.. <i>Annals of Medicine</i> , 2022 , 54, 1014-1035	1.5	0
2	Sarcoidosis-associated pulmonary hypertension and its treatment strategy. 2022 , 42, 24-28		0
1	An expert overview of pulmonary fibrosis in sarcoidosis. 2023 , 17, 119-130		0